Rigel Pharmaceuticals is a biotech firm focused on creating treatments for patients with blood disorders and cancer. Its flagship products include Tavalisse, for chronic immune thrombocytopenia, and Rezlidhia, targeting a specific form of acute myeloid leukemia. The company is also exploring treatments for autoimmune hemolytic anemia and COVID-19. Collaborating with institutions like Eli Lilly and The University of Texas MD Anderson Cancer Center, Rigel is at the forefront of developing innovative therapies. Founded in 1996, it is based in South San Francisco, California.
Thursday's top analyst upgrades and downgrades included Affirm, Bloom Energy, Carlyle, Dutch Bros, Fiserv, Hanesbrands, LyondellBasell Industries, Microsoft, Rigel Pharmaceutical, Target, Tesla and Twilio.
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) has announced that it will push forward with a midstage trial in the treatment of COVID-19.
Chris Lange Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair and Zynga.
